94 related articles for article (PubMed ID: 10933967)
21. Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application.
Yoon KJ; Hyatt JL; Morton CL; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2004 Aug; 3(8):903-9. PubMed ID: 15299073
[TBL] [Abstract][Full Text] [Related]
22. Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy.
Yoon KJ; Qi J; Remack JS; Virga KG; Hatfield MJ; Potter PM; Lee RE; Danks MK
Mol Cancer Ther; 2006 Jun; 5(6):1577-84. PubMed ID: 16818517
[TBL] [Abstract][Full Text] [Related]
23. Position and orientation independent transactivation by c-Myc.
Packham G; Bello-Fernandez C; Cleveland JL
Cell Mol Biol Res; 1994; 40(7-8):699-706. PubMed ID: 7787888
[TBL] [Abstract][Full Text] [Related]
24. APC-dependent regulation of ornithine decarboxylase in human colon tumor cells.
Fultz KE; Gerner EW
Mol Carcinog; 2002 May; 34(1):10-8. PubMed ID: 12112318
[TBL] [Abstract][Full Text] [Related]
25. Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance.
Wierdl M; Wall A; Morton CL; Sampath J; Danks MK; Schuetz JD; Potter PM
Mol Pharmacol; 2003 Aug; 64(2):279-88. PubMed ID: 12869632
[TBL] [Abstract][Full Text] [Related]
26. Helicobacter pylori-induced macrophage apoptosis requires activation of ornithine decarboxylase by c-Myc.
Cheng Y; Chaturvedi R; Asim M; Bussière FI; Scholz A; Xu H; Casero RA; Wilson KT
J Biol Chem; 2005 Jun; 280(23):22492-6. PubMed ID: 15843384
[TBL] [Abstract][Full Text] [Related]
27. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells.
Lutz W; Stöhr M; Schürmann J; Wenzel A; Löhr A; Schwab M
Oncogene; 1996 Aug; 13(4):803-12. PubMed ID: 8761302
[TBL] [Abstract][Full Text] [Related]
28. Regulation of human ornithine decarboxylase expression following prolonged quiescence: role for the c-Myc/Max protein complex.
Peña A; Wu S; Hickok NJ; Soprano DR; Soprano KJ
J Cell Physiol; 1995 Feb; 162(2):234-45. PubMed ID: 7822433
[TBL] [Abstract][Full Text] [Related]
29. A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38.
Stubdal H; Perin N; Lemmon M; Holman P; Bauzon M; Potter PM; Danks MK; Fattaey A; Dubensky T; Johnson L
Cancer Res; 2003 Oct; 63(20):6900-8. PubMed ID: 14583489
[TBL] [Abstract][Full Text] [Related]
30. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.
Yoon KJ; Krull EJ; Morton CL; Bornmann WG; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2003 Nov; 2(11):1171-81. PubMed ID: 14617791
[TBL] [Abstract][Full Text] [Related]
31. Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme.
Potter PM; Wolverton JS; Morton CL; Wierdl M; Danks MK
Cancer Res; 1998 Aug; 58(16):3627-32. PubMed ID: 9721871
[TBL] [Abstract][Full Text] [Related]
32. Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity.
Hyatt JL; Tsurkan L; Wierdl M; Edwards CC; Danks MK; Potter PM
Mol Cancer Ther; 2006 Sep; 5(9):2281-8. PubMed ID: 16985062
[TBL] [Abstract][Full Text] [Related]
33. Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis.
Sanghani SP; Quinney SK; Fredenburg TB; Sun Z; Davis WI; Murry DJ; Cummings OW; Seitz DE; Bosron WF
Clin Cancer Res; 2003 Oct; 9(13):4983-91. PubMed ID: 14581373
[TBL] [Abstract][Full Text] [Related]
34. Tumour promoter mediated altered expression and regulation of ornithine decarboxylase and S-adenosylmethionine decarboxylase in H-ras-transformed fibrosarcoma cell lines.
Voskas D; Mader R; Lee J; Hurta RA
Biochem Cell Biol; 2001; 79(1):69-81. PubMed ID: 11235918
[TBL] [Abstract][Full Text] [Related]
35. Transrepression of the N-myc expression by c-myc protein.
Kubota Y; Kim SH; Iguchi-Ariga SM; Ariga H
Biochem Biophys Res Commun; 1989 Aug; 162(3):991-7. PubMed ID: 2669755
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia-targeted over-expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT-11).
Matzow T; Cowen RL; Williams KJ; Telfer BA; Flint PJ; Southgate TD; Saunders MP
J Gene Med; 2007 Apr; 9(4):244-52. PubMed ID: 17397102
[TBL] [Abstract][Full Text] [Related]
37. N-myc regulation of type I insulin-like growth factor receptor in a human neuroblastoma cell line.
Chambéry D; Mohseni-Zadeh S; de Gallé B; Babajko S
Cancer Res; 1999 Jun; 59(12):2898-902. PubMed ID: 10383152
[TBL] [Abstract][Full Text] [Related]
38. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification.
Geerts D; Koster J; Albert D; Koomoa DL; Feith DJ; Pegg AE; Volckmann R; Caron H; Versteeg R; Bachmann AS
Int J Cancer; 2010 May; 126(9):2012-24. PubMed ID: 19960435
[TBL] [Abstract][Full Text] [Related]
39. Proficient metabolism of irinotecan by a human intestinal carboxylesterase.
Khanna R; Morton CL; Danks MK; Potter PM
Cancer Res; 2000 Sep; 60(17):4725-8. PubMed ID: 10987276
[TBL] [Abstract][Full Text] [Related]
40. Amplification of N-myc and ornithine decarboxylase genes in human neuroblastoma and hydroxyurea-resistant hamster cell lines.
Tonin PN; Yeger H; Stallings RL; Srinivasan PR; Lewis WH
Oncogene; 1989 Sep; 4(9):1117-21. PubMed ID: 2780050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
